ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...

Ionis Pharmaceuticals is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The ...

Rat disease models have played an integral role in scientific discovery and cancer research, including Nobel Prize–winning ...

An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs ...

Human genetics has become the primary engine for identifying lipid-lowering drug targets and predicting therapeutic success or failure. Monogenic family studies and population-based sequencing ...

RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...

Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene editing technologies enable ...

New England Biolabs (NEB®) has launched the NEBNext Companion Module for Oxford Nanopore Technologies Direct RNA Sequencing.

Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene ...

University of Arkansas scientists study soybean cyst nematode proteins to develop gene-edited soybean varieties resistant to ...

Single-cell RNA-seq AI analysis has become the default way to make sense of the millions of expression measurements a single experiment can now generate. Turning raw sequencing counts into ...